Santarus, Inc. (NASDAQ: SNTS) announced today the U.S. commercial launch of UCERISâ„˘ (budesonide) extended release tablets for the induction of remission in patients with active, mild to moderate ulcerative colitis. UCERIS was approved by the U.S. Food and Drug Administration on January 14, 2013.
UCERIS contains budesonide, a locally acting glucocorticosteroid, in a novel oral tablet formulation that utilizes proprietary MMXÂ® multi-matrix system colonic delivery technology. The approved dosing regimen for adult patients is one 9 mg tablet taken orally once daily in the morning for up to 8 weeks.
â€śWe believe that UCERIS fills an important therapeutic gap as a new prescription option available to physicians treating patients in the active phase of mild to moderate ulcerative colitis,â€ť said Wendell Wierenga, Ph.D., executive vice president of research and development. â€śIn our pivotal clinical studies, three times more patients achieved clinical remission and mucosal healing with UCERIS compared with patients taking placebo, and no clinically significant differences in glucocorticosteroid side effects were seen versus placebo after eight weeks of treatment.â€ť
William C. Denby, senior vice president of commercial operations said, â€śFor the commercial launch of UCERIS we have added 85 new sales representatives, increasing our total number of sales reps to 235. We will use the entire sales organization to promote UCERIS and ZEGERIDÂ® (omeprazole/sodium bicarbonate) to gastroenterologists, while also continuing to promote our three diabetes/metabolic products to endocrinologists and other physicians.â€ť
Mr. Denby added, â€śIn addition to our physician outreach, we recognize that informing patients with ulcerative colitis about UCERIS is key to motivating them to seek treatment for the active phase of their disease. To that end, we are implementing patient education programs through social media and medical information websites to provide patients with helpful information about treatment options.â€ť
UCERIS was developed in collaboration with Cosmo Technologies Limited, a subsidiary of Cosmo Pharmaceuticals S.p.A. Upon first commercial sale of UCERIS, $7 million is payable to Cosmo in cash or Santarus common stock, at Cosmoâ€™s option.
Important Safety Information About UCERIS
UCERIS is a prescription corticosteroid medicine used to help get mild to moderate ulcerative colitis under control. UCERIS is taken once daily in the morning with or without food for up to 8 weeks.
UCERIS is available by prescription only. For additional information, talk to your healthcare provider and see the Full Prescribing Information including Patient Labeling, available at www.santarus.com.
About Ulcerative Colitis
Ulcerative colitis is a form of chronic inflammatory bowel disease (IBD) that produces inflammation and ulcers along the inside of the colon, which can interfere with the normal function of the colon. The disease typically starts to manifest in patients as young adults. Ulcerative colitis is an intermittent disease with periods of exacerbated symptoms, or flares, and periods that are relatively symptom-free. Although the symptoms of ulcerative colitis may resolve without treatment, the disease usually requires medication to go into remission. According to the Crohnâ€™s and Colitis Foundation of America, as many as 700,000 people in the U.S. suffer from ulcerative colitis.
Santarus, Inc. is a specialty biopharmaceutical company focused on acquiring, developing and commercializing proprietary products that address the needs of patients treated by physician specialists. The company's current commercial efforts are focused on five products. UCERISâ„˘(budesonide) extended release tablets for the induction of remission in patients with active, mild to moderate ulcerative colitis and ZEGERIDÂ® (omeprazole/sodium bicarbonate) for the treatment of certain upper gastrointestinal disorders are promoted to gastroenterologists. GLUMETZAÂ® (metformin hydrochloride extended release tablets) and CYCLOSETÂ® (bromocriptine mesylate) tablets, which are indicated as adjuncts to diet and exercise to improve glycemic control in adults with type 2 diabetes, and FENOGLIDEÂ® (fenofibrate) tablets, which is indicated as an adjunct to diet to reduce high cholesterol, are promoted to endocrinologists and other physicians who treat patients with type 2 diabetes. Full prescribing and safety information for Santarusâ€™ products are available at www.santarus.com.
Santarusâ€™ product development pipeline includes the investigational drug RUCONESTÂ® (recombinant human C1 esterase inhibitor) for treatment of acute attacks of hereditary angioedema. The company expects to submit a biologics license application (BLA) to the U.S. Food and Drug Administration for RUCONEST in the first half of 2013. Santarus is also developing rifamycin SV MMXÂ®, which is in Phase III clinical testing for treatment of travelersâ€™ diarrhea. In addition, enrollment has been completed in a Phase I clinical program with SAN-300, the companyâ€™s investigational monoclonal antibody. More information about Santarus is available at www.santarus.com.
Santarus cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements.These forward-looking statements include statements regarding the timing and outcome of various matters relating to Santarus' development products, including the submission of a BLA for RUCONEST.
The inclusion of forward-looking statements should not be regarded as a representation by Santarus that any of its plans or objectives will be achieved.Actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in Santarusâ€™ business, including, without limitation: Santarus' ability to successfully launch UCERIS and generate revenues from UCERIS, ZEGERID, GLUMETZA and its other currently promoted commercial products and its authorized generic ZEGERID product; Santarus' ability to successfully advance the development of, obtain regulatory approval for and ultimately commercialize, its development-stage products, including the timing and outcome of the UCERIS Phase IIIb clinical study, the submission of the RUCONEST BLA and the second Phase III clinical study for rifamycin SV MMX; Santarus' ability to maintain patent protection for its products, including the difficulty in predicting the timing and outcome of ongoing patent litigation; Santarus' ability to achieve continued progress under its strategic alliances, and the potential for early termination of these agreements; Santarus' dependence on strategic partners for certain aspects of its development programs, including risks related to their financial stability; adverse side effects, inadequate therapeutic efficacy or other issues related to Santarus' products that could result in product recalls, market withdrawals or product liability claims; competition from other pharmaceutical or biotechnology companies and evolving market dynamics; other difficulties or delays relating to the development, testing, manufacturing and marketing of, and obtaining and maintaining regulatory approvals for, Santarus' products; fluctuations in quarterly and annual results; Santarus' ability to obtain additional financing as needed to support its operations or future product acquisitions; and other risks detailed in Santarusâ€™ prior press releases as well as in prior public periodic filings with the Securities and Exchange Commission.
You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof.All forward-looking statements are qualified in their entirety by this cautionary statement and Santarus undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof.This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.
SantarusÂ®, FENOGLIDEÂ®, UCERISâ„˘, and ZEGERIDÂ® are trademarks of Santarus, Inc.GLUMETZAÂ® is a trademark of Biovail Laboratories International S.r.l. licensed exclusively in the United States to Depomed, Inc.CYCLOSETÂ® is a trademark of VeroScience LLC.MMXÂ® is a trademark of Cosmo Technologies Limited. RUCONESTÂ® is a trademark of Pharming Group N.V.Business Wire
Last updated on: 14/02/2013